Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CORALVILLE, Iowa, Jan. 04, 2017 -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis Mickle, Ph.D., will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square.
Details of KemPharm's presentation are as follows:
| Event: | Biotech Showcase 2017 | |
| Date: | Tuesday, January 10, 2017 | |
| Time: | 3:00 p.m. (Pacific Time) | |
| Location: | Hilton San Francisco Union Square |
The presentation will be webcast and available on the Investor Relations section of the KemPharm website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other central nervous system (CNS) disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release (ER) prodrug of methylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD), and KP201/IR, an acetaminophen (APAP)-free formulation of the company’s immediate release (IR) abuse deterrent hydrocodone product, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
